Inhibition of PDZ domain-mediated interactions.

[1]  Katja Luck,et al.  The emerging contribution of sequence context to the specificity of protein interactions mediated by PDZ domains , 2012, FEBS letters.

[2]  D. Mukhopadhyay,et al.  Chemically modified peptides targeting the PDZ domain of GIPC as a therapeutic approach for cancer. , 2012, ACS chemical biology.

[3]  Bruce Randall Donald,et al.  Computational Design of a PDZ Domain Peptide Inhibitor that Rescues CFTR Activity , 2012, PLoS Comput. Biol..

[4]  D. J. Cook,et al.  Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain , 2012, Nature.

[5]  Patrik Lundström,et al.  A high-affinity, dimeric inhibitor of PSD-95 bivalently interacts with PDZ1-2 and protects against ischemic brain damage , 2012, Proceedings of the National Academy of Sciences.

[6]  M. Delepierre,et al.  Peptides targeting the PDZ domain of PTPN4 are efficient inducers of glioblastoma cell death. , 2011, Structure.

[7]  P. Schmieder,et al.  Photocontrol of contracting muscle fibers. , 2011, Angewandte Chemie.

[8]  U. Heinemann,et al.  Discovery, Structure–Activity Relationship Studies, and Crystal Structure of Nonpeptide Inhibitors Bound to the Shank3 PDZ Domain , 2011, ChemMedChem.

[9]  Andrew P. Rice,et al.  Emerging Theme: Cellular PDZ Proteins as Common Targets of Pathogenic Viruses , 2011, Journal of Virology.

[10]  B. Yan,et al.  Functional regulation of cystic fibrosis transmembrane conductance regulator-containing macromolecular complexes: a small-molecule inhibitor approach. , 2011, The Biochemical journal.

[11]  A. Kristensen,et al.  Cell-permeable and plasma-stable peptidomimetic inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction. , 2011, Journal of medicinal chemistry.

[12]  B. Imperiali,et al.  Biomimetic divalent ligands for the acute disruption of synaptic AMPAR stabilization. , 2011, Nature chemical biology.

[13]  Patrick R. Cushing,et al.  A stabilizing influence: CAL PDZ inhibition extends the half-life of ΔF508-CFTR. , 2010, Angewandte Chemie.

[14]  Prisca Boisguerin,et al.  Engineering peptide inhibitors to overcome PDZ binding promiscuity. , 2010, Angewandte Chemie.

[15]  W. Lu,et al.  Treatment of cerebral ischemia by disrupting ischemia-induced interaction of nNOS with PSD-95 , 2010, Nature Medicine.

[16]  B. Imperiali,et al.  Dynamic and specific interaction between synaptic NR2-NMDA receptor and PDZ proteins , 2010, Proceedings of the National Academy of Sciences.

[17]  Irina S. Moreira,et al.  Structure-activity relationships of a small-molecule inhibitor of the PDZ domain of PICK1. , 2010, Organic & biomolecular chemistry.

[18]  Mingjie Zhang,et al.  Extensions of PDZ domains as important structural and functional elements , 2010, Protein & Cell.

[19]  R. Huganir,et al.  AMPA receptor subunits define properties of state‐dependent synaptic plasticity , 2010, The Journal of physiology.

[20]  P. Schmieder,et al.  Design, synthesis, structure and binding properties of PDZ binding, cyclic beta-finger peptides. , 2010, Biochemical and biophysical research communications.

[21]  M. Iwata,et al.  A cyclic peptide targeted against PSD-95 blocks central sensitization and attenuates thermal hyperalgesia , 2010, Neuroscience.

[22]  Guang-yi Zhang,et al.  Transduced PDZ1 domain of PSD-95 decreases Src phosphorylation and increases nNOS (Ser847) phosphorylation contributing to neuroprotection after cerebral ischemia , 2010, Brain Research.

[23]  Harel Weinstein,et al.  Identification of a small-molecule inhibitor of the PICK1 PDZ domain that inhibits hippocampal LTP and LTD , 2009, Proceedings of the National Academy of Sciences.

[24]  C. Fairbanks,et al.  Disruption of nNOS‐PSD95 protein–protein interaction inhibits acute thermal hyperalgesia and chronic mechanical allodynia in rodents , 2009, British journal of pharmacology.

[25]  Y. Zong,et al.  Overexpression of PDZ1 domain prevents apoptosis of rat hippocampal neurons induced by kainic acid , 2009, Neuroscience Letters.

[26]  Jie J. Zheng,et al.  Sulindac inhibits canonical Wnt signaling by blocking the PDZ domain of the protein Dishevelled. , 2009, Angewandte Chemie.

[27]  Ling Wang,et al.  Targeting GIPC/Synectin in Pancreatic Cancer Inhibits Tumor Growth , 2009, Clinical Cancer Research.

[28]  Jie J. Zheng,et al.  Discovery and Characterization of a Small Molecule Inhibitor of the PDZ Domain of Dishevelled* , 2009, The Journal of Biological Chemistry.

[29]  B. Imperiali,et al.  A general screening strategy for peptide-based fluorogenic ligands: probes for dynamic studies of PDZ domain-mediated interactions. , 2009, Journal of the American Chemical Society.

[30]  R. Hannoush,et al.  Inhibition of Wnt signaling by Dishevelled PDZ peptides. , 2009, Nature chemical biology.

[31]  R. Johns,et al.  Cell-permeable peptide Tat-PSD-95 PDZ2 inhibits chronic inflammatory pain behaviors in mice. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[32]  P. Jemth,et al.  Modified peptides as potent inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction. , 2008, Journal of medicinal chemistry.

[33]  Chris Sander,et al.  A Specificity Map for the PDZ Domain Family , 2008, PLoS biology.

[34]  A. Rigotti,et al.  Overexpression of the PDZ1 Domain of PDZK1 Blocks the Activity of Hepatic Scavenger Receptor, Class B, Type I by Altering Its Abundance and Cellular Localization* , 2008, Journal of Biological Chemistry.

[35]  R. Huganir,et al.  PICK1 uncoupling from mGluR7a causes absence-like seizures , 2008, Nature Neuroscience.

[36]  Sudhir C. Sharma,et al.  A Chemical Library Approach to Organic‐Modified Peptide Ligands for PDZ Domain Proteins: A Synthetic, Thermodynamic and Structural Investigation , 2008, Chembiochem : a European journal of chemical biology.

[37]  Wendell A. Lim,et al.  β Strand Peptidomimetics as Potent PDZ Domain Ligands , 2006 .

[38]  James Inglese,et al.  Directed evolution of PDZ variants to generate high-affinity detection reagents. , 2005, Protein engineering, design & selection : PEDS.

[39]  Andrea Piserchio,et al.  Targeting specific PDZ domains of PSD-95; structural basis for enhanced affinity and enzymatic stability of a cyclic peptide. , 2004, Chemistry & biology.

[40]  M. Spaller,et al.  Thermodynamic profiling of conformationally constrained cyclic ligands for the PDZ domain. , 2004, Bioorganic & medicinal chemistry letters.

[41]  J. Hell,et al.  Disruption of the NMDA receptor–PSD-95 interaction in hippocampal neurons with no obvious physiological short-term effect , 2003, Neuropharmacology.

[42]  Irwin D Kuntz,et al.  A selective irreversible inhibitor targeting a PDZ protein interaction domain. , 2003, Journal of the American Chemical Society.

[43]  Seth G. N. Grant,et al.  PDZ Domain Proteins: Plug and Play! , 2003, Science's STKE.

[44]  G. Collingridge,et al.  Rapid and Differential Regulation of AMPA and Kainate Receptors at Hippocampal Mossy Fibre Synapses by PICK1 and GRIP , 2003, Neuron.

[45]  Yitao Liu,et al.  Treatment of Ischemic Brain Damage by Perturbing NMDA Receptor- PSD-95 Protein Interactions , 2002, Science.

[46]  R. Guy,et al.  Investigation of the PDZ domain ligand binding site using chemically modified peptides. , 2002, Bioorganic & medicinal chemistry letters.

[47]  R. Huganir,et al.  Cerebellar Long-Term Depression Requires PKC-Regulated Interactions between GluR2/3 and PDZ Domain–Containing Proteins , 2000, Neuron.

[48]  G. Kerchner,et al.  AMPA receptor–PDZ interactions in facilitation of spinal sensory synapses , 1999, Nature Neuroscience.

[49]  B. Kay,et al.  Cyclic Peptides as Non-carboxyl-terminal Ligands of Syntrophin PDZ Domains* , 1998, Journal of Biological Chemistry.

[50]  M. Sheng,et al.  PDZ domains and the organization of supramolecular complexes. , 2001, Annual review of neuroscience.